N-[[5-[[4-[[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]butanoylamino]sulfamoyl]thiophen-2-yl]methyl]naphthalene-1-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[[5-[[4-[[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]butanoylamino]sulfamoyl]thiophen-2-yl]methyl]naphthalene-1-carboxamide
• 化学式: C₂₆H₂₃ClF₃N₅O₄S₂
• 分子量: 626.1
• InChiKey: VWCPUUJLQDRDFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  41
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  166
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES
  申请人：ARKINSTALL Stephen

  公开号：US20090005426A1

  公开（公告）日：2009-01-01

  Sulfonyl hydrazide compounds according to formula I geometrical isomers thereof, optically active enantiomers thereof, diastereomers thereof, racemates thereof, and/or pharmaceutically acceptable salts thereof are useful in method for treating a neuronal disorder, an autoimmune disease, a cardiovascular disease, or cancer in a patient in need of such treatment.

  根据I式的磺酰肼化合物及其几何异构体、光学活性对映体、差向异构体、外消旋体和/或药学上可接受的盐，在治疗神经性疾病、自身免疫性疾病、心血管疾病或癌症的方法中，对于需要此类治疗的患者是有用的。
• US7432286B1
  申请人：——

  公开号：US7432286B1

  公开（公告）日：2008-10-07
• [EN] PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES<br/>[FR] DERIVES DE SULFONYL HYDRAZIDE ACTIFS AU PLAN PHARMACEUTIQUE
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2001023382A1

  公开（公告）日：2001-04-05

  The present invention is related to sulfonyl hydrazide derivatives for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl hydrazide derivatives. Said sulfonyl hydrazide derivatives are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonyl hydrazide derivatives as well as to methods of their preparation. In Formula (I) Ar?1 and Ar2¿ are independently from each other an unsubstituted or substituted aryl or heteroaryl group, X?1 and X2¿ are independently from each other O or S; R?1, R2, R3¿ are independently from each other hydrogen or a C¿1?-C6-alkyl substituent or R?1¿ forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar?1; or R2 and R3¿ form a substituted or unsubstituted 5-6-membered saturated or unsaturated ring; n is an integer from 0 to 5; G is selected from a group comprising or consisting of an unsubstituted or substituted 4-8 membered heterocycle containing at least one heteroatom, or G is a substituted or unsubstituted C¿1?-C6-alkyl group.